Biocon Limited
BIOCON
株式のランク
#3406
Biocon Limited functions as a biopharmaceutical firm, engaged in the production... Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
株価
$3.75
最終同期: 2026-10-19
時価総額
$5.13B
変化（1日）
-2.30%
変化（1年）
-9.79%
国
IN
取引 Biocon Limited (BIOCON)
カテゴリー
Healthcare
Biocon Limited（BIOCON）の収益
Jun 2026 時点の収益 TTM: $1.91B
Biocon Limited の最新の財務報告によると、現在の収益 (TTM) は $1.91B です。2024 年には $1.77B の収益があり、これは 2023 年の $1.36B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Biocon Limited の収益履歴（2004 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.91B | 6.92% |
| 2025 | $1.78B | 0.84% |
| 2024 | $1.77B | 30.15% |
| 2023 | $1.36B | 26.12% |
| 2022 | $1.08B | 10.49% |
| 2021 | $975.78M | 16.67% |
| 2020 | $836.33M | 5.32% |
| 2019 | $794.12M | 25.39% |
| 2018 | $633.30M | 5.55% |
| 2017 | $600.02M | 18.75% |
| 2016 | $505.27M | 2.04% |
| 2015 | $495.17M | -3.94% |
| 2014 | $515.48M | 12.70% |
| 2013 | $457.40M | 13.20% |
| 2012 | $404.08M | -21.72% |
| 2011 | $516.22M | 13.85% |
| 2010 | $453.41M | 67.79% |
| 2009 | $270.22M | 29.75% |
| 2008 | $208.27M | 9.73% |
| 2007 | $189.80M | 22.96% |
| 2006 | $154.36M | 4.28% |
| 2005 | $148.03M | 28.03% |
| 2004 | $115.62M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 561.69% |
US
|
|
| $2.23B | 16.78% |
US
|
|
| $15.74B | 725.22% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 215.60% |
NL
|
